LLY241129C510000
- 236.36
- 0.000.00%
Eli Lilly and Co Newsroom
Trump's Made His Health Picks. What They Mean for the Sector. -- Barrons.com
Drug Compounders Fight Drugmaker Efforts to Push Them Out of Market for GLP-1 Medications
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
(LLY) - Analyzing Eli Lilly's Short Interest
Hims & Hers up 18% Amid Optimism for Compounders With Makary FDA Pick
S&P 500, Dow Hit Records Right After Open | Live Stock
Eli Lilly's (LLY) Breakthroughs: Hedge Funds' New Healthcare Favorite
Jim Cramer on Eli Lilly and Company (LLY): 'It's Valuable'
Trump Nominates Marty Makary For FDA Commissioner
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Market Climbs, Bitcoin Close to $100k | Live Stock
novo-nordisk a/s (NVO.US) has signed a contract with Ypsomed to produce the next generation of injection pens for weight loss medication.
novo-nordisk a/s has announced that it has signed a contract with Ypsomed to produce the next generation of weight loss pen.
Novo Nordisk Said to Have Contracted Ypsomed to Make Next Gen Obesity Drug's Pens
Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock
Amgen (AMGN.US) weight loss drug is poised to launch, and Wall Street is eagerly awaiting the research results.
Amgen (AMGN.US) will soon release mid-term study data for the experimental weight loss drug MariTide, revealing a comparison of this drug with GLP-1 drugs from Eli Lilly (LLY.US) and novo-nordisk A/S (NVO.US).
In 2025, the global medical care industry is expected to usher in an investment boom, with a focus on Biotech.
Jefferies financial indicated that investor sentiment in the global medical care industry has significantly warmed up.
Express News | Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...